NIKKEI 225
38,923.03 +435.13 (+1.13%) HANG SENG
18,403.04 +323.43 (+1.79%) CRUDE OIL
74.17 -2.82 (-3.66%) GOLD FUTURES
2,372.80 +27.00 (+1.15%) DOW
38,280.67 -405.65 (-1.05%) Bitcoin GBP
53,875.39 +685.18 (+1.29%)
AGIO Dec 2024 17.500 put
| Previous close | 0.9800 |
| Open | 0.9800 |
| Bid | 0.0000 |
| Ask | 1.6000 |
| Strike | 17.50 |
| Expiry date | 2024-12-20 |
| Day's range | 0.9800 - 0.9800 |
| Contract range | N/A |
| Volume | |
| Open interest | 5 |
GlobeNewswireAgios Announces Phase 3 ENERGIZE-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia
– Study Achieved the Primary Endpoint; Mitapivat Demonstrated a Statistically Significant Transfusion Reduction Response Compared to Placebo – – Statistical Significance Achieved for All Key Secondary Endpoints Evaluating Additional Measures of Reduction of Transfusion Burden Compared to Placebo – – ENERGIZE-T is the First Phase 3 Study to Demonstrate Efficacy of an Oral, Disease-Modifying Treatment for Transfusion-Dependent Alpha- and Beta-Thalassemia – – As Part of Global Submission Strategy,
- GlobeNewswire
Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the company is scheduled to present at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024, at 1:20 p.m. ET. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. A r
ZacksAgios (AGIO) Up 23% on Selling Brain Cancer Drug Royalty
Agios Pharmaceuticals (AGIO) agrees to sell to Royalty Pharma the rights to royalties on potential net sales of a brain cancer drug that was sold to Servier in 2021.
